100 mg film-coated tablets, 150 mg film-coated tablets
- Antineoplastic agents. Protein kinase inhibitors.
- ERLOTINIB is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR also known as HER1) tyrosine kinase inhibitor.
- ERLOTINIB is approved for metastatic non-small cell lung cancer; pancreatic cancer.
- ERLOTINIB using can increase the life expectancy of these patients for more than 6 months compared to standard chemotherapy regimes platinum-drugs.